

Arden and Greater East Midlands Commissioning Support Unit in association with
Lincolnshire Clinical Commissioning Groups, Lincolnshire Community Health Services,
United Lincolnshire Hospitals Trust and Lincolnshire Partnership Foundation Trust

Lincolnshire *PACE* Shorts

Summary of PACEF decisions from December 2015

For further details see *PACE Bulletin* Volume 9 No 20 (December 2015)

Drug	Indication(s)	Traffic Light and <i>Joint Formulary</i> Status
Bevacizumab infusion (Avastin) (Roche)	For the treatment of relapsed, platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal cancer	RED Included in the Lincolnshire Joint Formulary for this indication subject to New Cancer Drugs Fund List criteria.
Desogestrel 75 microgram tablets (generic/ Cerelle (Consilient)/ Nacrez (Teva)/ Zellela (Morningside))	Oral contraception	GREEN lower cost. Approved for inclusion in the Lincolnshire Joint Formulary.
Desogestrel 75 microgram tablets (Aizea (Besins)/ Cerazette (MSD)/ Desomono (MedRx)/ Desorex (Somnex)/ Feanolla (Lupin))	Oral contraception	RED-RED higher cost. Not included in the Lincolnshire Joint Formulary.
Ethinylestradiol 20 microgram/desogestrel 150 microgram tablets (Bimizza (Morningside)/ Gedarel 20/150 (Consilient)/ Lestranyl 20/150 (Mylan))	Oral contraception	GREEN lower cost. Approved for inclusion in the Lincolnshire Joint Formulary.
Ethinylestradiol 20 microgram/desogestrel 150 microgram tablets (Munalea 20/150 (Lupin)/ Mercilon (MSD))	Oral contraception	RED-RED higher cost. Not included in the Lincolnshire Joint Formulary.
Ethinylestradiol 30 microgram/desogestrel 150 microgram tablets (Cimizt (Morningside)/Gedarel 30/15 (Consilient)/ Lestranyl (Mylan))	Oral contraception	GREEN lower cost. Approved for inclusion in the Lincolnshire Joint Formulary.
Ethinylestradiol 30 microgram/desogestrel 150 microgram tablets (Alenvona (Actavis)/ Munalea 30/150 (Lupin)/ Marvelon (MSD))	Oral contraception	RED-RED higher cost. Not included in the Lincolnshire Joint Formulary.
Ethinylestradiol 30 microgram/drospiridone 3mg tablets Acondro (Mylan)/ Dretine (Teva)/ Lucette (Consilient)/ Yacella (Morningside))	Oral contraception	GREEN lower cost. Approved for inclusion in the Lincolnshire Joint Formulary.

Ethinylestradiol 30 microgram/drospiridone 3mg tablets (Cleosensa (Actavis)/ Yasmin (Bayer))	Oral contraception	RED-RED higher cost. Not included in the Lincolnshire Joint Formulary.
Ethinylestradiol 20 microgram/gestodene 75 microgram tablets (Aidulan 20/75 (Lupin)/ Millinette 20/75 (Consilient)/ Sunya 20/75 (Stragen))	Oral contraception	GREEN lower cost. Approved for inclusion in the Lincolnshire Joint Formulary.
Ethinylestradiol 20 microgram/gestodene 75 microgram tablets (Femodette (Bayer))	Oral contraception	RED-RED higher cost. Not included in the Lincolnshire Joint Formulary.
Ethinylestradiol 30 microgram/gestodene 75 microgram tablets (Aidulan 30/75 (Lupin)/ Millinette 30/75 (Consilient)/ Katya 30/75 (Stragen))	Oral contraception	GREEN lower cost. Approved for inclusion in the Lincolnshire Joint Formulary.
Ethinylestradiol 30 microgram/gestodene 75 microgram tablets (Femodene (Bayer))	Oral contraception	RED-RED higher cost. Not included in the Lincolnshire Joint Formulary.
Ethinylestradiol 30 microgram/levonorgestrel 150 microgram tablets (Levest (Morningside)/ Rigevidon (Consilient))	Oral contraception	GREEN lower cost.
Ethinylestradiol 30 microgram/levonorgestrel 150 microgram tablets (Elevin (MedRx)/ Erlibelle (Actavis)/ Maexeni (Lupin)/ Microgynon 30 and Microgynon 30 ED (Bayer)/ Ovranelle (Pfizer))	Oral contraception	RED-RED higher cost. Not included in the Lincolnshire Joint Formulary.
Ethinylestradiol 35 microgram/norgestimate 250 microgram tablets (Lizinna (Morningside))	Oral contraception	GREEN lower cost. Approved for inclusion in the Lincolnshire Joint Formulary.
Ethinylestradiol 35 microgram/norgestimate 250 microgram tablets (Cilest 35/250 (Janssen-Cilag))	Oral contraception	RED-RED higher cost. Not included in the Lincolnshire Joint Formulary.
Levonorgestrel 1.5mg tablet	For emergency contraception within 72 hours of unprotected intercourse (UPI) or contraceptive failure.	GREEN Preferred first line. Approved for inclusion in the Lincolnshire Joint Formulary.
Mirabegron 25mg and 50mg tablets (Betmiga) (Astellas)	For urinary frequency, urgency and urge incontinence.	GREEN Included in the Lincolnshire Joint Formulary. Reserved for treatment of the symptoms of overactive bladder in those for whom antimuscarinics are contraindicated or clinically ineffective or have unacceptable side effects.

Pembrolizumab infusion (Keytruda)	For the treatment of advanced (unresectable or metastatic) melanoma in adults.	RED Included in the Lincolnshire Joint Formulary for this indication.
Ruxolitinib 5mg and 15mg tablets (Jakavi) (Novartis)	For the treatment of polycythaemia vera that is resistant to hydroxycarbamide or for people who cannot tolerate hydroxycarbamide	RED-RED. Not included in the Lincolnshire Joint Formulary for this indication.
Ulipristal 30mg tablets (EllaOne) (HRA Pharma)	For emergency contraception within 120 hours (5 days) of unprotected intercourse (UPI) or contraceptive failure	GREEN Included in the Lincolnshire Joint Formulary. Should only be used when patients present between 72 and 120 hours after UPI or contraceptive failure.
Vedolizumab 300mg injection (Entyvio) (Takeda)	For the treatment of adult patients with moderate to severe active Crohn's disease in those inadequately responsive or intolerant of conventional therapy or a tumour necrosis factor-alpha (TNF α) antagonist. For the treatment of adult patients with moderate to severe active ulcerative colitis in those inadequately responsive or intolerant of conventional therapy or a tumour necrosis factor-alpha (TNF α) antagonist.	RED Included in the Lincolnshire Joint Formulary for both indications subject to NICE criteria for initiation, review and discontinuation.

RED-RED: This signifies that a product is **not recommended** for prescribing in **either** primary or secondary care. All new products are classified as RED-RED pending assessment by PACEF.

RED: This signifies that a product has been approved for use within secondary care, tertiary care or a primary care hosted specialist service only and **should not be routinely prescribed in primary care**. RED drugs may be used within ULHT or LPFT subject to approval for use within each Trust. ULHT and LPFT reserve the right to determine whether or not RED drugs will be used within their Trusts. RED classification does not automatically signify that a drug will be available within secondary/tertiary care.

AMBER: This signifies that a drug has been approved for use in primary care **subject to specialist initiation; a shared care guideline (SCG) may also be required**. The main purpose of the SCG will be to clearly define both specialist and GP responsibilities. Not all AMBER drugs that require SCGs are currently covered by formal documents; PACEF are working to rectify this.

GREEN: This signifies a product that is **approved for initiation in either primary or secondary care**.

This bulletin has been created specifically to convey details of decisions taken at the Prescribing and Clinical Effectiveness Forum (PACEF) to all stakeholders across the Lincolnshire Healthcare Community in both primary and secondary care. Back issues of the *PACE Bulletin* and *PACE Shorts* are available through the PACEF website (<http://lincolnshire-pacef.nhs.uk>); follow the commissioning link to PACEF. Electronic copies of the *PACE Bulletin* are circulated to a wide readership via email. If you are not currently on our distribution list and wish to receive regular copies of PACEF publications please contact Sandra France on sandra.france@gemcsu.nhs.uk.

Google searching can be a quick and effective way of finding back numbers of the *PACE Bulletin* relevant to a specific topic of interest. Searchers are advised to use the official version of the *Bulletin* available from the PACEF website rather than depend on a potentially unreliable draft or variant found through Google or an alternative search engine.

The *Lincolnshire Joint Formulary* is available on line and is fully searchable; it can be accessed at www.lincolnshirejointformulary.nhs.uk

THIS DOCUMENT IS INTENDED FOR USE BY NHS HEALTHCARE PROFESSIONALS ONLY AND CANNOT BE USED FOR COMMERCIAL OR MARKETING PURPOSES WITHOUT PERMISSION